{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:21:24Z","timestamp":1791469284081,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008169","name":"Minneapolis Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.eclinm.2023.102016","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:41:25Z","timestamp":1686289285000},"page":"102016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing"],"prefix":"10.1016","volume":"60","author":[{"given":"Stefania","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"D'Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Rota-Scalabrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7332-5146","authenticated-orcid":false,"given":"Allison P.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bertazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Velluti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Saraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan R.","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102016_bib1","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102016_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102016_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood-2019-123465","article-title":"Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): griffin study update","volume":"134","author":"Voorhees","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102016_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102016_bib7","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.102016_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.eclinm.2023.102016_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eclinm.2023.102016_bib10","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2023.102016_bib11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2023.102016_bib12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102016_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Stetler-Stevenson","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.eclinm.2023.102016_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.eclinm.2023.102016_bib16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2023.102016_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211600","article-title":"Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma","volume":"14","author":"Rustad","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2023.102016_bib18","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1078-0432.CCR-20-2995","article-title":"Capture rate of V(D)J sequencing for minimal residual disease detection in multiple myeloma","volume":"28","author":"Hultcrantz","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2023.102016_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J\u00a0Mol Diagnostics"},{"key":"10.1016\/j.eclinm.2023.102016_bib20","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2019-123170","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib22","unstructured":"Adaptive Biotechnologies Corporation. clonoSEQ\u00ae assay technical information. https:\/\/www.clonoseq.com\/wp-content\/uploads\/2021\/08\/PNL-10027-03_clonoSEQ-Technical-Information.pdf."},{"key":"10.1016\/j.eclinm.2023.102016_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.eclinm.2023.102016_bib24","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.clml.2019.09.005","article-title":"Concordance of post-consolidation minimal residual disease rates by multiparametric flow cytometry and next-generation sequencing in CASSIOPEIA","volume":"19","author":"Avet-Loiseau","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.eclinm.2023.102016_bib25","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/cancers12082322","article-title":"Comparison of NGS and MFC methods: key metrics in multiple myeloma MRD assessment","volume":"12","author":"Kriegsmann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eclinm.2023.102016_bib26","first-page":"2142","article-title":"Minimal residual disease in multiple myeloma: state of the art and future perspectives","volume":"9","author":"Mina","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.eclinm.2023.102016_bib27","article-title":"Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia","volume":"5","author":"Cloos","year":"2018","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.eclinm.2023.102016_bib28","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eclinm.2023.102016_bib29","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2023.102016_bib31","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial","volume":"35","author":"Moreau","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102016_bib32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib33","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eclinm.2023.102016_bib34","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2023.102016_bib42","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2023.102016_bib35","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib36","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3324\/haematol.2017.166629","article-title":"Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation","volume":"102","author":"Chakraborty","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2023.102016_bib37","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.eclinm.2023.102016_bib38","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102016_bib39","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.eclinm.2023.102016_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) negativity in cassiopeia Part 1 and Part 2","volume":"138","author":"Avet Loiseau","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2023.102016_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023001931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023001931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:18:22Z","timestamp":1762899502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"alternative-id":["S2589537023001931"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102016","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102016"}}